论文部分内容阅读
目的探讨经动脉灌注速溶型表柔吡星混合微球对原发性肝癌进行栓塞治疗的安全性及近期疗效。方法对136例原发性肝癌患者行经动脉化疗栓塞(TACE),将速溶型表柔吡星10～60 mg与直径300～500μm的微球0.5～2 ml配置成混悬液,对肿瘤供血动脉进行栓塞。分别对患者手术前后血常规、肝功能、血清甲胎蛋白(AFP)水平、肿瘤的改变情况及栓塞相关并发症进行观察。结果TACE术后,患者的黄疸指数、丙氨酸、门冬氨酸转氨酶及血氨水平均有不同程度的升高;血清白蛋白、AFP水平明显降低;肿瘤不同程度坏死、缩小明显(P<0.05)。结论使用速溶型表柔吡星混合微球栓塞治疗原发性肝癌是安全的,近期疗效明显;但可造成一定程度的肝功能损害,应注意栓塞剂的用量及肝功能的保护。
Objective To investigate the safety and short-term curative effect of arterial infusion of epirubicin-loaded microspheres on primary hepatic carcinoma. Methods Thirty-six patients with primary liver cancer undergoing transcatheter arterial chemoembolization (TACE) were treated with suspension of 10 ~ 60 mg fast-acting doxorubicin and 0.5 ~ 2 ml microspheres with diameter of 300 ~ 500 μm. Embolism. The blood routine, liver function, serum level of AFP, tumor changes and embolism-related complications were observed before and after operation. Results After TACE, the patients’ jaundice index, alanine, aspartate aminotransferase and blood ammonia level all increased to some extent; the levels of serum albumin and AFP were significantly decreased; the tumors were necrosis at different degrees and decreased significantly (P <0.05 ). Conclusions It is safe to treat the primary hepatocellular carcinoma with instantaneous combination therapy of epirubicin and microspheres. The recent curative effect is obvious. However, it may cause some degree of liver damage. Attention should be paid to the dosage of embolization agent and the protection of liver function.